Page 54 - Read Online

Warawdekar et al. CTCs from patients with metastatic breast cancer

Gazzaniga P, Manso L, Zamarchi R, de Lascoiti AF, De Mattos-Arruda 16. Lankiewicz S, Rivero BG, Bocher O. Quantitative real-time RT-PCR
L, Ignatiadis M, Lebofsky R, van Laere SJ, Meier-Stiegen F, Sandri of disseminated tumor cells in combination with immunomagnetic
MT, Vidal-Martinez J, Politaki E, Consoli F, Bottini A, Diaz-Rubio cell enrichment. Mol Biotechnol 2006;34:15-27.
E, Krell J, Dawson SJ, Raimondi C, Rutten A, Janni W, Munzone E, 17. Zieglschmid V, Hollmann C, Gutierrez B, Albert W, Strothoff D,
Carañana V, Agelaki S, Almici C, Dirix L, Solomayer EF, Zorzino L, Gross E, Böcher O. Combination of immunomagnetic enrichment
Johannes H, Reis-Filho JS, Pantel K, Pierga JY, Michiels S. Clinical with multiplex RT-PCR analysis for the detection of disseminated
validity of circulating tumour cells in patients with metastatic breast tumor cells. Anticancer Res 2005;25:1803-10.
cancer: a pooled analysis of individual patient data. Lancet Oncol 18. Blassl C, Kuhlmann JD, Webers A, Wimberger P, Fehm T, Neubauer
2014;15:406-14. H. Gene expression profiling of single circulating tumor cells in
6. Rack B, Schindlbeck C, Jückstock J, Andergassen U, Hepp P, ovarian cancer-establishment of a multi-marker gene panel. Mol
Zwingers T, Friedl TW, Lorenz R, Tesch H, Fasching PA, Fehm T, Oncol 2016;10:1030-42.
Schneeweiss A, Lichtenegger W, Beckmann MW, Friese K, Pantel 19. Magbanua MJ, Park JW. Isolation of circulating tumor cells by
K, Janni W; SUCCESS Study Group. Circulating tumor cells predict immunomagnetic enrichment and fluorescence-activated cell sorting
survival in early average-to-high risk breast cancer patients. J Natl (IE/FACS) for molecular profiling. Methods 2013;64:114-8.
Cancer Inst 2014;106. 20. Takao M, Takeda K. Enumeration, characterization, and collection
7. Giuliano M, Giordano A, Jackson S, De Giorgi U, Mego M, Cohen of intact circulating tumor cells by cross contamination-free flow
EN, Gao H, Anfossi S, Handy BC, Ueno NT, Alvarez RH, De Placido cytometry. Cytometry A 2011;79:107-17.
S, Valero V, Hortobagyi GN, Reuben JM, Cristofanilli M. Circulating 21. Watanabe M, Uehara Y, Yamashita N, Fujimura Y, Nishio K, Sawada
tumor cells as early predictors of metastatic spread in breast cancer T, Takeda K, Koizumi F, Koh Y. Multicolor detection of rare tumor
patients with limited metastatic dissemination. Breast Cancer Res cells in blood using a novel flow cytometry-based system. Cytometry
2014;16:440. A 2014;85:206-13.
8. Lorente D, Olmos D, Mateo J, Bianchini D, Seed G, Fleisher M, 22. Aerts J, Wynendaele W, Paridaens R, Christiaens MR, van den Bogaert
Danila DC, Flohr P, Crespo M, Figueiredo I, Miranda S, Baeten W, van Oosterom AT, Vandekerckhove F. A real-time quantitative
K, Molina A, Kheoh T, McCormack R, Terstappen LW, Scher HI, reverse transcriptase polymerase chain reaction (RT-PCR) to detect
de Bono JS. Decline in circulating tumor cell count and treatment breast carcinoma cells in peripheral blood. Ann Oncol 2001;12:39-46.
outcome in advanced prostate cancer. Eur Urol 2016;70:985-92. 23. Strati A, Markou A, Parisi C, Politaki E, Mavroudis D, Georgoulias
9. Čapoun O, Mikulová V, Jančíková M, Honová H, Kološtová K, V, Lianidou E. Gene expression profile of circulating tumor cells in
Sobotka R, Michael P, Zima T, Hanuš T, Soukup V. Prognosis of breast cancer by RT-qPCR. BMC Cancer 2011;11:422.
castration-resistant prostate cancer patients-use of the AdnaTest(R) 24. Hu Y, Fan L, Zheng J, Cui R, Liu W, He Y, Li X, Huang S. Detection
system for detection of circulating tumor cells. Anticancer Res of circulating tumor cells in breast cancer patients utilizing
2016;36:2019-26. multiparameter flow cytometry and assessment of the prognosis of
10. Agelaki S, Kalykaki A, Markomanolaki H, Papadaki MA, Kallergi G, patients in different CTCs levels. Cytometry A 2010;77:213-9.
Hatzidaki D, Kalbakis K, Mavroudis D, Georgoulias V. Efficacy of 25. Greenfield LJ, Proctor MC, Saluja A. Clinical results of greenfield
lapatinib in therapy-resistant HER2-positive circulating tumor cells in filter use in patients with cancer. Cardiovasc Surg 1997;5:145-9.
metastatic breast cancer. PLoS One 2015;10:e0123683. 26. Osta WA, Chen Y, Mikhitarian K, Mitas M, Salem M, Hannun YA,
11. Grande E, Capdevila J, Castellano D, Teulé A, Durán I, Fuster J, Cole DJ, Gillanders WE. EpCAM is overexpressed in breast cancer
Sevilla I, Escudero P, Sastre J, García-Donas J, Casanovas O, Earl and is a potential target for breast cancer gene therapy. Cancer Res
J, Ortega L, Apellaniz-Ruiz M, Rodriguez-Antona C, Alonso-Gordoa 2004;64:5818-24.
T, Díez JJ, Carrato A, García-Carbonero R. Pazopanib in pretreated
advanced neuroendocrine tumors: a phase II, open-label trial of the 27. Alberti S, Ambrogi F, Boracchi P, Fornili M, Querzoli P, Pedriali M, La
spanish task force group for neuroendocrine tumors (GETNE). Ann Sorda R, Lattanzio R, Tripaldi R, Piantelli M, Biganzoli E, Coradini
Oncol 2015;26:1987-93. D. Cytoplasmic Trop-1/Ep-CAM overexpression is associated with a
12. Alix-Panabieres C, Pantel K. Challenges in circulating tumour cell favorable outcome in node-positive breast cancer. Jpn J Clin Oncol
research. Nat Rev Cancer 2014;14:623-31. 2012;42:1128-37.
13. Harouaka R, Kang Z, Zheng SY, Cao L. Circulating tumor cells: 28. Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail
advances in isolation and analysis, and challenges for clinical NY, Picus J, Morse M, Mitchell E, Miller MC, Doyle GV, Tissing
applications. Pharmacol Ther 2014;141:209-21. H, Terstappen LW, Meropol NJ. Relationship of circulating tumor
14. Kagan M, Howard D, Bendele T, Rao C, Terstappen LWMM. cells to tumor response, progression-free survival, and overall
Circulating tumor cells as cancer markers, a sample preparation and survival in patients with metastatic colorectal cancer. J Clin Oncol
analysis system. In: Diamandis EP, Fritsche HA, Lilja H, Chan DW, 2008;26:3213-21.
Schwartz M, editors. Tumor markers: physiology, pathobiology, 29. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller
technology, and clinical applications. Washington (DC): AACC Press; MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF.
2002. p. 495-8. Circulating tumor cells, disease progression, and survival in metastatic
15. Riethdorf S, Fritsche H, Müller V, Rau T, Schindlbeck C, Rack B, breast cancer. N Engl J Med 2004;351:781-91.
Janni W, Coith C, Beck K, Jänicke F, Jackson S, Gornet T, Cristofanilli 30. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing
M, Pantel K. Detection of circulating tumor cells in peripheral blood H, Doyle GV, Terstappen LW, Pienta KJ, Raghavan D. Circulating
of patients with metastatic breast cancer: a validation study of the tumor cells predict survival benefit from treatment in metastatic
cellsearch system. Clin Cancer Res 2007;13:920-8. castration-resistant prostate cancer. Clin Cancer Res 2008;14:6302-9.

Journal of Cancer Metastasis and Treatment ¦ Volume 3 ¦ February 23, 2017 33